(240) Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma
Introduction: Protein vaccines show great promise for tumor immunotherapy (1). However, current protein vaccines often induce limited antitumor T cell responses. Here, we introduce PROTAVs designed to enhance antigen proteolytic processing and cross-presentation, thereby boosting T cell responses for effective immunotherapy against melanoma. These modular conjugates consist of melanoma antigens, E3 ligase-binding ligands, and linkers. When co-delivered via lipid nanoparticles (LNPs) alongside bi-adjuvant, PROTAVs significantly improved specific CD8+ T cells response in mice.
Learning Objectives:
Upon completion, PROTAVs can be as a versatile platform for developing cancer therapeutic vaccines.
